• 1
    National Institutes of Health/National Heart, Lung, And Blood Institute. Global Initiative for Asthma. Global strategy for asthma management and prevention (revised 2007). Available at: Accessed 1 October 2009.
  • 2
    National Heart Lung and Blood Institute/National Asthma Education and Prevention Program (NHLBI/NAEPP). Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. NIH Publication No. 07-4051. Bethesda, MD: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute, 2007.
  • 3
    Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 2005;115:459465.
  • 4
    Holt PG, Macaubas C, Stumbles PA, Sly PD. The role of allergy in the development of asthma. Nature 1999;402(Suppl. 6760):B12B17.
  • 5
    Novak N, Bieber T. Allergic and nonallergic forms of atopic diseases. J Allergy Clin Immunol 2003;112:252262.
  • 6
    Prussin C, Griffith DT, Boesel KM, Lin H, Foster B, Casale TB. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol 2003;112:11471154.
  • 7
    Kitawaki T, Kadowaki N, Sugimoto N, Kambe N, Hori T, Miyachi Y et al. IgE-activated mast cells in combination with pro-inflammatory factors induce Th2-promoting dendritic cells. Int Immunol 2006;18:17891799.
  • 8
    Genentech Inc. Xolair® (Omalizumab) for subcutaneous injection. Full Prescribing Information (US), July 2007. Available at: Accessed 1 October 2009.
  • 9
    Novartis Europharm Limited. Xolair® (Omalizumab) Product Information (Summary of Product Characteristics -Annex I), 2009. Accessed 1 October 2009.
  • 10
    Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309316.
  • 11
    Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005;60:302308.
  • 12
    Molimard M, De BF, Didier A, Le Gros V. Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France. Respir Med 2008;102:7176.
  • 13
    MacGlashan DW Jr, Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997;158:14381445.
  • 14
    Lin H, Boesel KM, Griffith DT, Prussin C, Foster B, Romero FA et al. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J Allergy Clin Immunol 2004;113:297302.
  • 15
    Djukanović R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004;170:583593.
  • 16
    Prussin C, Metcalfe DD. 4. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 2003;111(Suppl. 2):S486S494.
  • 17
    Adamko DJ, Odemuyiwa SO, Vethanayagam D, Moqbel R. The rise of the phoenix: the expanding role of the eosinophil in health and disease. Allergy 2005;60:1322.
  • 18
    Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002;360:17151721.
  • 19
    Louis R, Lau LC, Bron AO, Roldaan AC, Radermecker M, Djukanović R. The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med 2000;161:916.
  • 20
    Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184190.
  • 21
    Solèr M, Matz J, Townley R, Buhl R, O’Brien J, Fox H et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18:254261.
  • 22
    Zeldin R, Massanari M, Blogg M, Jimenez P, Geba G. Treatment of moderate-severe asthma with omalizumab is associated with a decrease in peripheral blood eosinophils [abstract]. Eur Respir J 2007;30(Suppl. 51):353s,P2132.
  • 23
    Leung DY, Martin RJ, Szefler SJ, Sher ER, Ying S, Kay AB et al. Dysregulation of interleukin 4, interleukin 5, and interferon gamma gene expression in steroid-resistant asthma. J Exp Med 1995;181:3340.
  • 24
    Van Rensen ELJ, Evertse CE, Van Schadewijk WA, Van Wijngaarden S, Ayre G, Mauad T et al. Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment. Allergy 2009;64:7280.
  • 25
    Noga O, Hanf G, Brachmann I, Klucken AC, Kleine-Tebbe, J, Rosseau S et al. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol 2006;117:14931499.
  • 26
    Broide DH, Paine MM, Firestein GS. Eosinophils express interleukin 5 and granulocyte macrophage-colony-stimulating factor mRNA at sites of allergic inflammation in asthmatics. J Clin Invest 1992;90:14141424.
  • 27
    Conesa A, Tassinari P, Aldrey O, Taylor P, Bianco NE, De Sanctis JB. Interleukin-2 induces peroxide production by primed normodense eosinophils of patients with asthma. Allergy Asthma Proc 2003;24:2733.
  • 28
    Simon HU, Plotz S, Simon D, Seitzer U, Braathen LR, Menz G et al. Interleukin-2 primes eosinophil degranulation in hypereosinophilia and Wells’ syndrome. Eur J Immunol 2003;33:834839.
  • 29
    Brightling CE, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID, Bradding P. Interleukin-4 and -13 expression is co-localized to mast cells within the airway smooth muscle in asthma. Clin Exp Allergy 2003;33:17111716.
  • 30
    Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben, TY, Karp CL et al. Interleukin-13: central mediator of allergic asthma. Science 1998;282:22582261.
  • 31
    Noga O, Hanf G, Kunkel G. Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int Arch Allergy Immunol 2003;131:4652.
  • 32
    Humbert M, Durham SR, Ying S, Kimmitt P, Barkans J, Assoufi B et al. IL-4 and IL-5 mRNA and protein in bronchial biopsies from patients with atopic and nonatopic asthma: evidence against “intrinsic” asthma being a distinct immunopathologic entity. Am J Respir Crit Care Med 1996;154:14971504.
  • 33
    Lee YC, Lee KH, Lee HB, Rhee YK. Serum levels of interleukins (IL)-4, IL-5, IL-13, and interferon-gamma in acute asthma. J Asthma 2001;38:665671.
  • 34
    Yasruel Z, Humbert M, Kotsimbos TC, Ploysongsang Y, Minshall E, Durham SR et al. Membrane-bound and soluble alpha IL-5 receptor mRNA in the bronchial mucosa of atopic and nonatopic asthmatics. Am J Respir Crit Care Med 1997;155:14131418.
  • 35
    Coffman RL, Carty J. A T cell activity that enhances polyclonal IgE production and its inhibition by interferon-gamma. J Immunol 1986;136:949954.
  • 36
    Larche M, Robinson DS, Kay AB. The role of T lymphocytes in the pathogenesis of asthma. J Allergy Clin Immunol 2003;111:450463.
  • 37
    Noga O, Hanf G, Kunkel G, Kleine-Tebbe J. Basophil histamine release decreases during omalizumab therapy in allergic asthmatics. Int Arch Allergy Immunol 2008;146:6670.
  • 38
    Holgate ST. The Quintiles Prize Lecture 2004. The identification of the adenosine A2B receptor as a novel therapeutic target in asthma. Br J Pharmacol 2005;145:10091015.
  • 39
    Prieto L, Gutierrez V, Colas C, Tabar A, Pérez-Francés C, Bruno L et al. Effect of omalizumab on adenosine 5′-monophosphate responsiveness in subjects with allergic asthma. Int Arch Allergy Immunol 2006;139:122131.
  • 40
    Boulet LP, Chapman KR, Côté J, Kalra S, Bhagat R, Swystun VA et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 1997;155:18351840.
  • 41
    Fahy JV, Fleming HE, Wong HH, Liu JT, Su JQ, Reimann J et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997;155:18281834.
  • 42
    Kay AB, Ali FR, Heaney LG, Benyahia F, Soh CP, Renz H et al. Airway expression of calcitonin gene-related peptide in T-cell peptide-induced late asthmatic reactions in atopics. Allergy 2007;62:495503.
  • 43
    Plewako H, Arvidsson M, Petruson K, Oancea I, Holmberg K, Adelroth E et al. The effect of omalizumab on nasal allergic inflammation. J Allergy Clin Immunol 2002;110:6871.
  • 44
    Feuchtinger T, Bartz H, Von BA, Riedinger F, Brauburger J, Stenglein S et al. Treatment with omalizumab normalizes the number of myeloid dendritic cells during the grass pollen season. J Allergy Clin Immunol 2003;111:428430.
  • 45
    Bez C, Schubert R, Kopp M, Ersfeld Y, Rosewich M, Kuehr J et al. Effect of anti-immunoglobulin E on nasal inflammation in patients with seasonal allergic rhinoconjunctivitis. Clin Exp Allergy 2004;34:10791085.
  • 46
    Kopp MV, Brauburger J, Riedinger F, Beischer D, Ihorst G, Kamin W et al. The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis. J Allergy Clin Immunol 2002;110:728735.
  • 47
    Ädelroth E, Rak S, Haahtela T, Aasand G, Rosenhall L, Zetterstrom O et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000;106:253259.
  • 48
    Kuehr J, Brauburger J, Zielen S, Schauer U, Kamin W, Von Berg A et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002;109:274280.
  • 49
    Ong YE, Menzies-Gow A, Barkans J, Benyahia F, Ou TT, Ying S et al. Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge. J Allergy Clin Immunol 2005;116:558564.
  • 50
    Varghese M, Lieberman P. The effects of repeat omalizumab administration on skin test positivity and the assessment of the safety of administration in patients with positive skin tests to mouse antigen. Allergy Asthma Proc 2007;28:320323.
  • 51
    Hayek B, Heil PM, Laimer M, Maurer D, Hultsch D, Stingl G. Omalizumab-induced downregulation of IgE/FcɛRI on dendritic cells in patients with atopic dermatitis. XXIII EAACI Congr Abstr Book 2004;224:744 [abstract].
  • 52
    Barnes PJ, Woolcock AJ. Difficult asthma. Eur Respir J 1998;12:12091218.
  • 53
    Huang YC, Leyko B, Frieri M. Effects of omalizumab and budesonide on markers of inflammation in human bronchial epithelial cells. Ann Allergy Asthma Immunol 2005;95:443451.